S-Michael  ||| S:0 E:10 ||| JJ
additions  ||| S:10 E:20 ||| NNS
to  ||| S:20 E:23 ||| TO
chiral  ||| S:23 E:30 ||| VB
dehydroalanines  ||| S:30 E:46 ||| VBN
as  ||| S:46 E:49 ||| IN
an  ||| S:49 E:52 ||| DT
entry  ||| S:52 E:58 ||| NN
to  ||| S:58 E:61 ||| TO
glycosylated  ||| S:61 E:74 ||| VB
cysteines  ||| S:74 E:84 ||| NNS
and  ||| S:84 E:88 ||| CC
a  ||| S:88 E:90 ||| DT
sulfa-Tn  ||| S:90 E:99 ||| JJ
antigen  ||| S:99 E:107 ||| NNS
mimic  ||| S:107 E:113 ||| VBP
Stereoselective  ||| S:113 E:129 ||| JJ
sulfa-Michael  ||| S:129 E:143 ||| JJ
addition  ||| S:143 E:152 ||| NN
of  ||| S:152 E:155 ||| IN
appropriately  ||| S:155 E:169 ||| RB
protected  ||| S:169 E:179 ||| VBN
thiocarbohydrates  ||| S:179 E:197 ||| VBN
to  ||| S:197 E:200 ||| TO
chiral  ||| S:200 E:207 ||| VB
dehydroalanines  ||| S:207 E:223 ||| NN
has  ||| S:223 E:227 ||| VBZ
been  ||| S:227 E:232 ||| VBN
developed  ||| S:232 E:242 ||| VBN
as  ||| S:242 E:245 ||| IN
a  ||| S:245 E:247 ||| DT
key  ||| S:247 E:251 ||| JJ
step  ||| S:251 E:256 ||| NN
in  ||| S:256 E:259 ||| IN
the  ||| S:259 E:263 ||| DT
synthesis  ||| S:263 E:273 ||| NN
of  ||| S:273 E:276 ||| IN
biologically  ||| S:276 E:289 ||| JJ
important  ||| S:289 E:299 ||| JJ
cysteine  ||| S:299 E:308 ||| JJ
derivatives ||| S:308 E:319 ||| NNS
,  ||| S:319 E:321 ||| ,
such  ||| S:321 E:326 ||| JJ
as  ||| S:326 E:329 ||| IN
S- ||| S:329 E:331 ||| NNP
( ||| S:331 E:332 ||| -LRB-
β-D-glucopyranosyl ||| S:332 E:350 ||| NNP
) ||| S:350 E:351 ||| -RRB-
-D-cysteine ||| S:351 E:362 ||| NNP
,  ||| S:362 E:364 ||| ,
which  ||| S:364 E:370 ||| WDT
has  ||| S:370 E:374 ||| VBZ
not  ||| S:374 E:378 ||| RB
been  ||| S:378 E:383 ||| VBN
synthesized  ||| S:383 E:395 ||| VBN
to  ||| S:395 E:398 ||| TO
date ||| S:398 E:402 ||| NN
,  ||| S:402 E:404 ||| ,
and  ||| S:404 E:408 ||| CC
S- ||| S:408 E:410 ||| NNP
( ||| S:410 E:411 ||| -LRB-
2-acetamido-2-deoxy-α-D-galactopyranosyl ||| S:411 E:451 ||| NNP
) ||| S:451 E:452 ||| -RRB-
-L-cysteine ||| S:452 E:463 ||| NNP
,  ||| S:463 E:465 ||| ,
which  ||| S:465 E:471 ||| WDT
could  ||| S:471 E:477 ||| MD
be  ||| S:477 E:480 ||| VB
considered  ||| S:480 E:491 ||| VBN
as  ||| S:491 E:494 ||| IN
a  ||| S:494 E:496 ||| DT
mimic  ||| S:496 E:502 ||| NN
of  ||| S:502 E:505 ||| IN
Tn  ||| S:505 E:508 ||| NNP
antigen ||| S:508 E:515 ||| NN
.  ||| S:515 E:517 ||| .
The  ||| S:517 E:521 ||| DT
corresponding  ||| S:521 E:535 ||| JJ
diamide  ||| S:535 E:543 ||| JJ
derivative  ||| S:543 E:554 ||| NN
was  ||| S:554 E:558 ||| VBD
also  ||| S:558 E:563 ||| RB
synthesized  ||| S:563 E:575 ||| JJ
and  ||| S:575 E:579 ||| CC
analyzed  ||| S:579 E:588 ||| VBD
from  ||| S:588 E:593 ||| IN
a  ||| S:593 E:595 ||| DT
conformational  ||| S:595 E:610 ||| JJ
viewpoint ||| S:610 E:619 ||| NN
,  ||| S:619 E:621 ||| ,
and  ||| S:621 E:625 ||| CC
its  ||| S:625 E:629 ||| PRP$
bound  ||| S:629 E:635 ||| JJ
state  ||| S:635 E:641 ||| NN
with  ||| S:641 E:646 ||| IN
a  ||| S:646 E:648 ||| DT
lectin  ||| S:648 E:655 ||| NN
was  ||| S:655 E:659 ||| VBD
studied ||| S:659 E:666 ||| VBN
.  ||| S:666 E:668 ||| .
